Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

Background. Chemotherapy with platinum agent and etoposide for small-cell lung cancer (SCLC) is supposed to be associated with intermediate risk (10-20%) of febrile neutropenia. Primary prophylaxis with granulocyte colonystimulating factors (G-CSFs) is not routinely recommended by the treatment guid...

Full description

Bibliographic Details
Main Authors: Kukec Renata Rezonja, Grabnar Iztok, Vovk Tomaz, Mrhar Ales, Kovac Viljem, Cufer Tanja
Format: Article
Language:English
Published: Sciendo 2015-06-01
Series:Radiology and Oncology
Subjects:
small cell lung cancer
platinum-etoposide chemotherapy
etoposide
febrile neutropenia
plasma drug concentration
Online Access:https://doi.org/10.2478/raon-2014-0050

Internet

https://doi.org/10.2478/raon-2014-0050

Similar Items